La présentation est en train de télécharger. S'il vous plaît, attendez

La présentation est en train de télécharger. S'il vous plaît, attendez

PROTECT Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation : a randomised.

Publié parSylvaine Beausoleil Modifié depuis plus de 6 années

Présentations similaires

Présentation au sujet: "PROTECT Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation : a randomised."— Transcription de la présentation:

1 PROTECT Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation : a randomised multicentre open-label controlled trial. Camenzind E, et al. ESC 2012

2 PROTECT Méthodologie Objectif Etude Critères d’inclusion
Évaluation du risque de thrombose de 2 endoprothèses coronaires actives (stents actifs) Etude Première grande étude prospective, randomisée, multicentrique, internationale (196 sites, 5 continents) Critères d’inclusion Population de coronariens représentative des situations cliniques quotidiennes Sténoses mono et pluritronculaires Aucune limitation sur le nombre de lésions par vaisseau PROTECT Camenzind E, et al. ESC 2012

3 Zotarolimus stent Endeavour® n = 4357
Schéma de l’étude Zotarolimus stent Endeavour® n = 4357 Sirolimus stent Cypher® n = 4352 n = 8709 PROTECT 30 j 6 mois 12 mois 18 mois 24 mois 30 mois 3 ans 4 ans 5 ans Camenzind E, et al. ESC 2012

4 PROTECT Résultats Critère Principal :
Thrombose de Stent certaine ou probable à 3 ans 5% PROTECT 2,5% Cypher® Sirolimus 1,79% p = 0,224 Endeavor® Zotarolimus 1,42% 1 2 3 Délai après ATL initiale (ans) Camenzind E, et al. ESC 2012

5 Résultats Thrombose de Stent certaine ou probable avant et à 1 an 5% PROTECT 2,5% p = 0,06 Cypher® Sirolimus 1,1% p < 0,001 Endeavor® Zotarolimus 0,3% 1 2 3 Délai après ATL initiale (ans) Camenzind E, et al. ESC 2012

6 Conclusion Aucune différence significative entre les 2 endoprothèses (stents) actifs pour les thromboses certaines ou probables après 3 ans de suivi. L’analyse détaillée fait apparaître néanmoins une fréquence croissante des thromboses au cours du temps, ce qui conforte le principe d’un suivi prolongé. PROTECT Camenzind E, et al. ESC 2012

Télécharger ppt "PROTECT Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation : a randomised."

Présentations similaires

Cas clinique 6.

Cas clinique 6.
CLOTS 3 Effectiveness of intermittent pneumatic compression in reduction of risk of deep venous thrombosis in patients who have had a stroke (CLOTS 3):

CLOTS 3 Effectiveness of intermittent pneumatic compression in reduction of risk of deep venous thrombosis in patients who have had a stroke (CLOTS 3):
STREAM Fibrinolysis or Primary PCI in ST-segment Elevation Myocardial Infarction Armstrong P.W, et al. N Engl J Med 2013 ; 368 : 1379-87 Armstrong PW.

STREAM Fibrinolysis or Primary PCI in ST-segment Elevation Myocardial Infarction Armstrong P.W, et al. N Engl J Med 2013 ; 368 : Armstrong PW.
unstable angina undergoing PCI.

unstable angina undergoing PCI.
EXCELLENT The randomized comparison of 6-month vs 12-month duration of dual antiplatelet therapy after the implantation of drug eluting stent. Gwon H-C,

EXCELLENT The randomized comparison of 6-month vs 12-month duration of dual antiplatelet therapy after the implantation of drug eluting stent. Gwon H-C,
ISAR-TEST 4 Intracoronary stenting and antirestenotic results : test efficacy of 3 limus-eluting stents Mehilli J et al.

ISAR-TEST 4 Intracoronary stenting and antirestenotic results : test efficacy of 3 limus-eluting stents Mehilli J et al.
ATOLL Acute STEMI treated with primary PCI and intravenous enoxaparin or UFH to lower ischemic and bleeding events at short and long-term follow-up. Montalescot.

ATOLL Acute STEMI treated with primary PCI and intravenous enoxaparin or UFH to lower ischemic and bleeding events at short and long-term follow-up. Montalescot.
ABOARD* Essai multicentrique randomisé comparant une stratégie invasive immédiate versus différée chez des patients présentant un syndrome coronarien aigu.

ABOARD* Essai multicentrique randomisé comparant une stratégie invasive immédiate versus différée chez des patients présentant un syndrome coronarien aigu.
ATLAS ACS 2 -TIMI 51 Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome.  Présentée.

ATLAS ACS 2 -TIMI 51 Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome.  Présentée.
TITRATION DU CLOPIDOGREL Tailored Clopidogrel Loading Dose according to Platelet Reactivity Monitoring Decrease Early Stent Thrombosis. Paganelli F et.

TITRATION DU CLOPIDOGREL Tailored Clopidogrel Loading Dose according to Platelet Reactivity Monitoring Decrease Early Stent Thrombosis. Paganelli F et.
Clopidogrel Quand et combien? André Kokis MD FRCPC FACC Hémodynamicien et cardiologue du CHUM.

Clopidogrel Quand et combien? André Kokis MD FRCPC FACC Hémodynamicien et cardiologue du CHUM.
SYNTAX The synergy between percutaneous coronary intervention with TAXUS and cardiac surgery. Primary endpoint results at one year in the randomized cohort.

SYNTAX The synergy between percutaneous coronary intervention with TAXUS and cardiac surgery. Primary endpoint results at one year in the randomized cohort.
CARESS-AMI Combined Abciximab Reteplase Stent Study in Acute Myocardial Infarction ESC 2007. CARESS-AMI.

CARESS-AMI Combined Abciximab Reteplase Stent Study in Acute Myocardial Infarction ESC CARESS-AMI.
Registre MATRIX Long term safety of DES (drug eluting stents) in off-label use : results of the MATRIX registry. Dangas G.D et al. American College of.

Registre MATRIX Long term safety of DES (drug eluting stents) in off-label use : results of the MATRIX registry. Dangas G.D et al. American College of.
TRITON-TIMI 38 Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes.

TRITON-TIMI 38 Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes.
ATLANTIC : ticagrelor en traitement pré-hospitalier (2)

ATLANTIC : ticagrelor en traitement pré-hospitalier (2)
ISAR REACT 3A A trial of reduced dose of unfractioned heparin in biomarker negative patients undergoing percutaneous coronary intervention. Schulz S et.

ISAR REACT 3A A trial of reduced dose of unfractioned heparin in biomarker negative patients undergoing percutaneous coronary intervention. Schulz S et.
PRODIGY Prolonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia study Valgimigli M et al. ESC 2011.

PRODIGY Prolonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia study Valgimigli M et al. ESC 2011.
Mass-DAC Drug-Eluting and Bare Metal Stenting in Diabetes Mellitus : Results from the Mass-DAC Registry. Mauri L et al. AHA 2008.

Mass-DAC Drug-Eluting and Bare Metal Stenting in Diabetes Mellitus : Results from the Mass-DAC Registry. Mauri L et al. AHA 2008.
TRITON-TIMI 38 Evaluation of Prasugrel Compared with Clopidogrel in Patients with Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention:

TRITON-TIMI 38 Evaluation of Prasugrel Compared with Clopidogrel in Patients with Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention:

Présentations similaires

Annonces Google